Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 10/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19998095 | 0.84 | TGFBR1 (0.41) | TGFBR1KDM4EGLAGAACYP1A2 | |
| SCHEMBL2177180 | 0.82 | KEAP1 (0.46) | TGFBR1KDM4EGLAGAACHEK1 | |
| SCHEMBL24091996 | 0.79 | TGFBR1 (0.39) | TGFBR1KDM4EGLAGAACYP1A2 | |
| SCHEMBL4253156 | 0.79 | FYN (0.41) | TGFBR1FYNCHEK1CHEK2ABL1 | |
| SCHEMBL4258498 | 0.79 | FYN (0.40) | FYNCHEK1CHEK2ABL1TYR | |
| SCHEMBL4253252 | 0.79 | FYN (0.40) | FYNCHEK1CHEK2ABL1TYR | |
| SCHEMBL16368027 | 0.76 | TGFBR1 (0.43) | TGFBR1FYNKDM4EGLAGAA | |
| SCHEMBL10238918 | 0.75 | CYP1A2 (0.56) | TGFBR1KDM4EGLAGAACYP1A2 | |
| SCHEMBL5030840 | 0.75 | TGFBR1 (0.53) | TGFBR1KDM4EGLAGAACYP1A2 | |
| SCHEMBL23106898 | 0.74 | PRMT5 (0.40) | FYNKDM4EGLAGAACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PI4KA, PIP4K2A | TGFBR1 444/4885FYN 115/4885KDM4E 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.